Treating the small airways

Respiration

Volumn 84, Issue 6, 2012, Pages 441-453

  Usmani, Omar S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Inhaled drug delivery; Small particle aerosols

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LONG ACTING DRUG; MOMETASONE FUROATE; PREDNISONE; SALBUTAMOL;

AEROSOL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG DEPOSITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG SCINTISCANNING; MEDICAL NEBULIZER; METERED DOSE INHALER; PARTICLE SIZE; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMALL AIRWAY DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AEROSOLS; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84869389761     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000343629     Document Type: Article

References (106)

1. Hamid Q: Pathogenesis of small airways in asthma. Respiration 2012; 84: 4-11
2. Baraldo S, Turato G, Saetta M: Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration 2012; 84: 89-97
3. Verbanck S: Physiological measurement of the small airways. Respiration 2012; 84: 177- 188
4. in 't Veen JC, Beekman AJ, Bel EH, Sterk PJ: Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000; 161: 1902-1906 (Pubitemid 30418127)
5. Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER: Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584-588 (Pubitemid 20109142)
6. Hyde DM, Hamid Q, Irvin CG: Anatomy, pathology, and physiology of the tracheobronchial tree: Emphasis on the distal airways. J Allergy Clin Immunol 2009; 124(6 suppl): S72-S77
7. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ: Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510 (Pubitemid 26391205)
8. Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG: Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001; 163: 1551-1556 (Pubitemid 32578754)
9. Kaminsky DA, Irvin CG, Gurka DA, Feldsien DC, Wagner EM, Liu MC, Wenzel SE: Peripheral airway responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995; 152: 1784-1790
10. Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID: Alveolar nitric oxide in adults with asthma: Evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005; 25: 986-991 (Pubitemid 40823772)
11. Fritscher LG, Rodrigues MT, Zamel N, Chapman KR: The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med 2009; 103: 296-300
12. Gandevia B: Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51(7 suppl):13-20
13. Grossman J: The evolution of inhaler technology. J Asthma 1994; 31: 55-64 (Pubitemid 24087756)
14. Dalby R, Suman J: Inhalation therapy: Technological milestones in asthma treatment. Adv Drug Deliv Rev 2003; 55: 779-791 (Pubitemid 36776793)
15. Hanania NA, Wittman R, Kesten S, Chapman KR: Medical personnel's knowledge of and ability to use inhaling devices. Metereddose inhalers, spacing chambers, and breathactuated dry powder inhalers. Chest 1994; 105: 111-116 (Pubitemid 24029087)
16. Plaza V, Sanchis J, Roura P, Molina J, Calle M, Quirce S, Viejo JL, Caballero F, Murio C: Physicians' knowledge of inhaler devices and inhalation techniques remains poor in Spain. J Aerosol Med Pulm Drug Deliv 2012; 25: 16-22
17. Zainudin BM, Biddiscombe M, Tolfree SE, Short M, Spiro SG: Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45: 469-473 (Pubitemid 20225175)
18. Labiris NR, Dolovich MB: Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications (review). Br J Clin Pharmacol 2003; 56: 588-599 (Pubitemid 37491710)
19. Gerrity TR, Lee PS, Hass FJ, Marinelli A, Werner P, Lourenço RV: Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol 1979; 47: 867-873 (Pubitemid 10236261)
20. Heyder J: Assessment of airway geometry with inert aerosols. J Aerosol Med 1989; 2: 89-97
21. Chrystyn H: Anatomy and physiology in delivery: Can we define our targets? Allergy 1999; 54(suppl 49):82-87 (Pubitemid 29292498)
22. Usmani OS, Biddiscombe MF, Barnes PJ: Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am J Respir Crit Care Med 2005; 172: 1497-1504 (Pubitemid 43076536)
23. Molina MJ, Rowland FS: Stratospheric sink for chlorofluoromethanes: Chlorine atomcatalysed destruction of ozone. Nature 1974; 249: 810-812
24. Dolovich M: New delivery systems and propellants. Can Respir J 1999; 6: 290-295
25. Zeidler M, Corren J: Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004; 3: 35-44 (Pubitemid 38444330)
26. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W: Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28: 1042-1050 (Pubitemid 46335529)
27. Martin RJ: Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002; 109(2 suppl):S447-S460 (Pubitemid 34155294)
28. Yang TT, Li S, Wyka B, Kenyon D: Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001; 14: 487-494 (Pubitemid 34008105)
29. Cripps A, Riebe M, Schulze M, Woodhouse R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(suppl B):S3-S9 (Pubitemid 30599243)
30. Acerbi D, Brambilla G, Kottakis I: Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20: 290-303 (Pubitemid 46242202)
31. Leach CL, Davidson PJ, Boudreau RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-1353 (Pubitemid 29011427)
32. Leach CL, Bethke TD, Boudreau RJ, et al: Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19: 117-126 (Pubitemid 43993378)
33. de Vries TW, Rottier BL, Gjaltema D, Hagedoorn P, Frijlink HW, de Boer AH: Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution. Respir Med 2009; 103: 1167-1173
34. Lewis D, Brambilla G, Church T, Meakin B: Beclomethasone dipropionate and formoterol association within a combination HFA solution MDI. Respir Drug Deliv 2006; 3: 939- 942
35. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ: Lung deposition of hydrofluoroalkane- 134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: A cross-over study in healthy volunteers. Chest 2002; 122: 510-516 (Pubitemid 35002128)
36. Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD: Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane- 134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012; 108: 195-200
37. Newman S, Salmon A, Nave R, Drollmann A: High lung deposition of 99m Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100: 375-384 (Pubitemid 43239871)
38. Verbanck S, Kalsi HS, Biddiscombe MF, Agnihotri V, Belkassem B, Lacor C, Usmani OS: Inspiratory and expiratory aerosol deposition in the upper airway. Inhal Toxicol 2011; 23: 104-111
39. De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, et al: Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010; 23: 137- 148
40. Häussermann S, Acerbi D, Brand P, Herpich C, Poli G, Sommerer K, Meyer T: Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med 2007; 20: 331-341 (Pubitemid 47463186)
41. Laube BL, Swift DL, Wagner HN, Norman PS, Adams GK: The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. Am Rev Respir Dis 1986; 133: 740-743 (Pubitemid 16116495)
42. Richards R, Haas A, Simpson S, Britten A, Renwick A, Holgate S: Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. Thorax 1988; 43: 611-616
43. Nicolini G, Scichilone N, Bizzi A, Papi A, Fabbri LM: Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations. Ther Clin Risk Manag 2008; 4: 855-864
44. Hoshino M: Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 2010; 59: 59-66
45. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ: Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 2003; 95: 2106-2112 (Pubitemid 37310397)
46. Goldman MD, Saadeh C, Ross D: Clinical applications of forced oscillation to assess peripheral airway function. Respir Physiol Neurobiol 2005; 148: 179-194 (Pubitemid 41135872)
47. Paredi P, Goldman M, Alamen A, Ausin P, Usmani OS, Pride NB, Barnes PJ: Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax 2010; 65: 263-267
48. Fahy JV, Wong H, Liu J, Boushey HA: Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995; 152: 53-58
49. Global Initiative for Asthma (GINA): GINA Report, Global Strategy for Asthma Management and Prevention, revised 2011. http:// www.ginasthma.org
50. BTS and Scottish Intercollegiate Guidelines Network (SIGN): British Guideline on the Management of Asthma British Thoracic Society revised 2012 http://www.britthoracic. org.uk/guidelines/asthma-guidelines. Aspx
51. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN): British Guideline on the Management of Asthma, revised 2012. http://www.britthoracic. org.uk/guidelines/asthma-guidelines. aspx. 51 Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC: Stepping down inhaled corticosteroids in asthma: Randomised controlled trial. BMJ 2003; 326: 1115-1118 (Pubitemid 36613440)
52. Lee DK, Borade PS, Promnitz DA, Currie GP: Stepping-down inhaled corticosteroid therapy in stable asthma: A secondary care perspective. QJM 2005; 98: 771-772 (Pubitemid 41548556)
53. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, Jenkins CR: Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)- agonist. Respir Med 2010; 104: 1110-1120
54. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfourgeres JL, Attali V: Maintaining asthma control in persistent asthma: Comparison of three strategies in a 6-month double- blind randomised study. Respir Med 2008; 102: 1124-1131
55. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M: Asthma control can be maintained when fluticasone propionate/ salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006; 117: 563-570 (Pubitemid 43340219)
56. Foresi A, Mastropasqua B, Chetta A, D'Ippolito R, Testi R, Olivieri D, Pelucchi A: Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma. Chest 2005; 127: 117-124 (Pubitemid 41724564)
57. Fardon T, Haggart K, Lee DK, Lipworth BJ: A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007; 101: 1218-1228 (Pubitemid 46679499)
58. Fowler SJ, Currie GP, Lipworth BJ: Stepdown therapy with low-dose fluticasone salmeterol combination or medium dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002; 109: 929-935 (Pubitemid 34634301)
59. Olsson B: Aerosol particle generation from dry powder inhalers: Can they equal pressurized metered dose inhalers? J Aerosol Med 1995; 8(suppl 3):S13-S18
60. Leach CL: Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998; 92(suppl A):3-8
61. Bateman E, Karpel J, Casale T, Wenzel S, Banerji D: Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006; 129: 1176-1187
62. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ: Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-743 (Pubitemid 27396409)
63. Nelson HS, Bernstein IL, Fink J, et al: Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: A double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group. Chest 1998; 113: 1264-1271 (Pubitemid 28223814)
64. Nelson HS, Busse WW, deBoisblanc BP, et al: Fluticasone propionate powder: Oral corticosteroid- sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103: 267-275 (Pubitemid 29095832)
65. Papi A, Nicolini G, Crimi N, Fabbri L, Olivieri D, Rossi A, Paggiaro P: Step-down from high dose fixed combination therapy in asthma patients: A randomized controlled trial. Respir Res 2012; 13: 54
66. Dahlén S-E, Dahlén B, Drazen JM: Asthma treatment guidelines meet the real world. N Engl J Med 2011; 364: 1769-1770
67. Ware JH, Hamel MB: Pragmatic trials - guides to better patient care? N Engl J Med 2011; 364: 1685-1687
68. Allegra L, Cremonesi G, Girbino G, Ingrassia E, Marsico S, Nicolini G, Terzano C; PRISMA (PRospectIve Study on asthMA control) Study Group. Real-life prospective study on asthma control in Italy: Cross-sectional phase results. Respir Med 2012; 106: 205-214
69. Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, Olivieri D: Effects of beclomethasone/ formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis 2011; 6: 503-509
70. Mahler DA, Witek TJ Jr: The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103 (Pubitemid 40776229)
71. Hogg JC, Macklem PT, Thurlbeck WM: Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360
72. Barnes PJ: Small airways in COPD. N Engl J Med 2004; 350: 2635-2637 (Pubitemid 38787995)
73. GOLD Report Executive Summary. Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/ guidelines-global-strategy- for-diagnosismanagement. Html
74. O'Donnell DE, Lam MIU, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549 (Pubitemid 29380670)
75. Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V: Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med 2010; 104: 1858- 1868
76. Adcock IM, Maneechotesuwan K, Usmani O: Molecular interactions between glucocorticoids and long-acting beta2-agonists (review). J Allergy Clin Immunol 2002; 110(6 suppl):S261-S268 (Pubitemid 35471714)
77. Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ: Protective effects of a glucocorticoid on downregulation of pulmonary beta-2 adrenergic receptors in vivo. J Clin Invest 1995; 96: 99-106
78. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LM: Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010
79. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL: Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293- 1299 (Pubitemid 35284621)
80. Papakonstantinou E, Klagas I, Karakiulakis G, Hostettler K, S'ng CT, Kotoula V, Savic S, Tamm M, Roth M: Steroids and - 2 agonists regulate hyaluronan metabolism in asthma airway smooth muscle cells. Am J Respir Cell Mol Biol 2012, E-pub ahead of print. 81 Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704-712
81. Orsida BE, Ward C, Li X, Bish R, Wilson JW, Thien F, Walters EH: Effect of a long-acting - 2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164: 117-121
82. Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, Bailey M, Wilson JW, Walters EH: An antiinflammatory effect of salmeterol, a long-acting - 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-1499
83. Baraniuk JN, Ali M, Brody D, et al: Glucocorticosteroids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155: 704-710 (Pubitemid 27085823)
84. Greening AP, Ind PW, Northfield M, Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224 (Pubitemid 24229008)
85. Woolcock A, Lundback B, Ringdal N, Jacques LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488 (Pubitemid 26141329)
86. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411
87. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CG, Postma DS, Pauwels RA, Tattersfield AE, Ullman A: Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043
88. Shrewsbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373 (Pubitemid 30261116)
89. Matz J, Emmett A, Rickard K, Kalberg C: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107: 783-789 (Pubitemid 32436910)
90. Calverley PM, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789 (Pubitemid 46294610)
91. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J: Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103: 41-49
92. Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, Curran-Everett D, Erzurum SC, Gaston BM, Israel E, Jarjour NN, Moore WC, Peters SP, Teague WG, Wenzel SE, National Heart, Lung, and Blood Institute Severe Asthma Research Program: Lung function in adults with stable but severe asthma: Air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394-403 (Pubitemid 351231486)
93. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM, ICAT SE study group: Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182-1188 (Pubitemid 47374029)
94. Verbanck S, Thompson BR, Schuermans D, Kalsi H, Biddiscombe M, Stuart-Andrews C, Hanon S, Van Muylem A, Paiva M, Vincken W, Usmani O: Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung. Thorax 2012; 67: 789-795
95. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852 (Pubitemid 35178607)
96. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD: Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008; 31: 416-469
97. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, López-Collazo E, Alvarez-Sala R: Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506-512
98. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ: The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy 2010; 40: 242-250
99. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O'Brien CD: Interpreting clinical trial results of patient-perceived onset of effect in asthma: Methods and results of a Delphi panel. Curr Med Res Opin 2009; 25: 1563-1571
100. Meyer RJ: U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease. COPD 2005; 2: 47-49 (Pubitemid 40776222)
101. Norman GR: The relation between the minimally important difference and patient benefit. COPD 2005; 2: 69-73 (Pubitemid 40776226)
102. King GG: Tomographic imaging of small airways. Respiration 2012;84:265-274
103. Gasparini S, Zuccatosta L, Bonifazi M, Bolliger CT: Bronchoscopic treatment of emphysema: state of the art. Respiration 2012; 84: 250-263
104. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL: Rhinitis therapy and the prevention of hospital care for asthma: A case-control study. J Allergy Clin Immunol 2004; 113: 415-419 (Pubitemid 38338943)
105. Compalati E, Ridolo E, Passalacqua G, Braido F, Villa E, Canonica GW: The link between allergic rhinitis and asthma: The united airways disease. Expert Rev Clin Immunol 2010; 6: 413-423
106. Usmani OS: Unravelling the small airways: structure-function-treatment relationships in asthma and COPD. Respiration 2012; 84: 1-3.